Industry Resources | January 6, 2020
Warning Letter: Liveyon Labs, Inc.
On December 5, 2019, the Office of Biological Products Operations sent a warning letter to Liveyon Labs Inc. The letter outlines that during an inspection of Liveyon Labs Inc. and Liveyon LLC conducted in May 2019, the Food and Drug Administration documented that the organization processes human umbilical cord blood derived cellular products PURE® and PURE PRO® for allogeneic use . . .